Chaminda Salgado

Vice President of CMC • T-cypher Bio

Chaminda Salgado is a highly experienced CMC Leader, with 14 years of experience in CMC biological assets and a further 6 years of experience in Cell & Gene therapies, ensuring the smooth flow of programs from Lead development through PoC (PhII). Accountable for ensuring delivery of the Process, Product and CMC submissions by managing cross-functional teams consisting of Reg Affairs, Up/Downstream development & validation, Formulation, Cell Line Development, Cell Banking, Analytical development, QC and QA.

Chaminda is a Change Agent and well renowned Process Improver, running the Bioassay and Genomics departments at NDA-Analytics, with a great track record of consistently delivering innovative, high impact and pragmatic efficiency gains whilst growing the business. Chaminda is experienced in forecasting potential bottlenecks and resource issues for customers downstream and he is also a recognised expert and pioneer of Real-Time PCR technology with vast experience in leading CMC Drug Development of Biopharmaceutical projects.

Also speaking

Pierre-Olivier Boyer

Head of France & Head of Business Excellence Europe • PTC Therapeutics

Matthieu Coutet

Managing Partner • AdBio Partners

William Shingler

Head of Patient and Cell Management • Autolus Therapeutics

Event Info


Event Brochure

Take a look at the 2023 Event Brochure for Advanced Therapies Europe.

Download the 2023 Speaker List

Download the 2023 Speaker List for Advanced Therapies Europe here.